Skip to main content
Equibles
ANEB logo

ANEB · Anebulo Pharmaceuticals, Inc. · Metrics

Track ANEB — free

Use ANEB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANEB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.43 +0.07 (+20.56%) At close · Mar 2
Rebalance outlook locked
Market Cap
$13.46M
Shares
40.78M
Volume · Mar 2 21.4K Avg daily vol (3M) 99.57K

ANEB metrics

39 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.43
Market cap
$13.46M

Price action

20 metrics
Price change (1W)
-0.2%
Price change (30D)
—
Price change (3M)
-81.6%
Price change (6M)
-82.6%
Price change (YTD)
-57.0%
Price change (1Y)
-62.6%
Trailing year
Price change (5Y)
—
52-week high
$3.33
52-week low
$0.36
Change from 52-week high
-87.0%
Change from 52-week low
+20.6%
Annualized volatility
133.0%
Annualized volatility (3M)
145.2%
Beta
-1.5
RSI (14D)
28.5
Price vs SMA 50
-54.3%
Price vs SMA 200
-76.4%
Avg volume (3M)
99,568
Relative volume
0.2
Average dollar volume
$101,144

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
40.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.7
reciprocal yield 59.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-59.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$9.10M
Net income (TTM)
−$7.98M
Trailing 12 months
Diluted EPS (TTM)
$-0.18
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.28

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+49.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-100.5%
Return on assets
-84.7%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-38.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$9.04M
Latest balance sheet
Cash & equivalents
$9.04M
Total assets
$9.42M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.84M
Capital expenditures (TTM)
—
R&D (TTM)
$3.74M
SG&A (TTM)
—
Stock compensation (TTM)
$1.03M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1815974 CUSIP 034569103 Visit website Investor relations